Severe warm autoimmune hemolytic anemia in COVID-19 managed with least incompatible RBC product and glucocorticoids

Hsieh, Tien‐Chan; Sostin, Oleg

doi:10.1007/s00277-021-04457-4

Cited by 8 publications

(8 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Corticosteroids are considered as first‐line therapy in WAHA 1,8 . In patients with WAHA refractory to corticosteroids, rituximab can be utilized as second‐line therapy.…”

Section: Discussionmentioning

confidence: 99%

Warm autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis/macrophage activation syndrome occurring after COVID19 infection and administration of Casirivimab + Imdevimab (COVID19 monoclonal antibody)

Swartz,

Novelli

2024

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageWarm Autoimmune Hemolytic Anemia (WAHA) is the most common form of autoimmune hemolysis and there is a growing body of evidence of an association between SARS‐CoV‐2 infection, WAHA and a hyperinflammatory state, including hemophagocytic lymphohistiocytosis/macrophage activation syndrome. However, there is no literature to date of WAHA or hyperinflammatory state following administration of anti‐SARS‐CoV‐2 monoclonal antibody treatment. This report documents a case of a patient with history of WAHA who developed brisk hemolysis and a hyperinflammatory state consistent with hemophagocytic lymphohistiocytosis/macrophage activation syndrome after COVID‐19 infection and treatment with an anti‐SARS‐CoV‐2 monoclonal antibody. He was successfully treated with multimodal treatment involving steroids, intravenous immunoglobulins, rituximab, anakinra, and vincristine with resolution of the hemolysis.

show abstract

“…Corticosteroids are considered as first‐line therapy in WAHA 1,8 . In patients with WAHA refractory to corticosteroids, rituximab can be utilized as second‐line therapy.…”

Section: Discussionmentioning

confidence: 99%

Warm autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis/macrophage activation syndrome occurring after COVID19 infection and administration of Casirivimab + Imdevimab (COVID19 monoclonal antibody)

Swartz,

Novelli

2024

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…El tratamiento de la AIHA se basa en el empleo de glucocorticoides a dosis altas y en caso de resultados insatisfactorios se puede optar por inmunoglobulina humana IV. Como fármaco de segunda línea se sugiere rituximab 14,20 .…”

Section: Discussionunclassified

Anemia hemolítica mixta posterior a infección por SARS-CoV-2 en un paciente infectado por virus de hepatitis B

Sánchez-Insfrán¹,

Daiub²,

Llanes³

2022

Rev. chil. infectol.

View full text Add to dashboard Cite

Sin financiamiento. Los autores declaran no poseer conflictos de intereses.Recibido: (segunda versión) 4 de junio de 2022 / Aceptado: 30 de julio de 2022 ResumenVarón de 36 años, diabético, con antecedente de 10 días de evolución de una neumonía por COVID-19. Fue trasladado por disnea, somnolencia y astenia de 24 horas de aparición. Presentaba taquicardia, taquipnea, palidez e ictericia generalizada. Se confirmó una anemia severa normocítica normocrómica, acompañado de hemólisis intravascular (test de Coombs directo positivo, LDH y bilirrubina indirecta aumentada, consumo de haptoglobina). Además, tenía un HBsAg positivo, con IgM anti-HBc negativo y transaminasas elevadas. El paciente inició tratamiento con tenofovir, además de metilprednisolona, inmunoglobulina humana IV y múltiples microtransfusiones, con buena evolución.

show abstract

“…The average time between the onset of COVID‐19 symptoms to the development of AIHA is around eight days. 7 Of note, most patients who developed AIHA had a moderate‐severe COVID‐19, and the inflammatory markers were notably elevated 7 , 8 ; however, AIHA can occur even in patients with asymptomatic COVID‐19. 6 Moreover, a few of those patients had preexisting comorbidities, such as chronic lymphatic leukemia idiopathic thrombocytopenic purpura, or lymphomas, suggesting a possible underlying immunological phenomenon.…”

Section: Discussionmentioning

confidence: 99%

“… 9 , 10 The evidence for the treatment of COVID‐19‐related AIHA is scarce and based mainly on the reported cases, although glucocorticoid therapy has been shown to be very effective and most of the cases improved dramatically after commencing glucocorticoid therapy. 5 , 6 , 7 , 8 …”

Section: Discussionmentioning

confidence: 99%

“…Based on one review, only 20 cases of COVID‐19‐related AIHA are found in the literature. The average time between the onset of COVID‐19 symptoms to the development of AIHA is around eight days 7 . Of note, most patients who developed AIHA had a moderate‐severe COVID‐19, and the inflammatory markers were notably elevated 7,8 ; however, AIHA can occur even in patients with asymptomatic COVID‐19 6 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Concomitant autoimmune hemolytic anemia and pulmonary embolism associated with mild COVID‐19: A case report

Al-Mashdali

Ata

Yassin

2021

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Severe warm autoimmune hemolytic anemia in COVID-19 managed with least incompatible RBC product and glucocorticoids

Cited by 8 publications

References 7 publications

Warm autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis/macrophage activation syndrome occurring after COVID19 infection and administration of Casirivimab + Imdevimab (COVID19 monoclonal antibody)

Warm autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis/macrophage activation syndrome occurring after COVID19 infection and administration of Casirivimab + Imdevimab (COVID19 monoclonal antibody)

Anemia hemolítica mixta posterior a infección por SARS-CoV-2 en un paciente infectado por virus de hepatitis B

Concomitant autoimmune hemolytic anemia and pulmonary embolism associated with mild COVID‐19: A case report

Contact Info

Product

Resources

About